Literature DB >> 6649399

Effect of injection site on the bioavailability of an oxytetracycline formulation in ruminant calves.

J F Nouws, T B Vree.   

Abstract

The oxytetracycline (OTC) disposition was studied in a group of six calves following the administration of an oxytetracycline-10 per cent formulation (i) intravenously (i.v.), (ii) subcutaneously (s.c.) in the lateral neck, and intramuscularly (i.m.) in (iii) the lateral neck, (iv) the shoulder (M. triceps brachii), and (v) the buttock (M. semitendineus). The dose levels used for the intravenous route and other routes were respectively 17.0 +/- 2.3 and 18.3 +/- 1.25 mg OTC/kg. The peak OTC concentrations (Cmax) were achieved with the s.c. and i.m. routes between 4 and 8 hours after injection, the highest being found after application in the shoulder (Cmax:6.9 +/- 0.82 microgram/ml plasma). The Cmax for the s.c. and other i.m. routes in application was similar to each other, ranging from 5.0 to 5.5 micrograms/ml plasma. For different points in time after injection the partial bioavailability was calculated. At 52 h post injection (p.i.) maximal bioavailability was observed for the i.m. shoulder route, viz. 98.1 +/- 7.0 per cent of the administered dose, while at 76 h p.i. similar bioavailabilities were achieved for the i.m. neck and shoulder route, namely 93.3 +/- 8.9 and 99.4 +/- 4.2 per cent, respectively. The lowest bioavailability (83.1 +/- 13.4 per cent) was obtained following the i.m. buttock route at 76 p.i. An obvious irritating effect was observed after s.c. application in the neck an di.m. injection in the buttock, which had disappeared at 5 days p.i. It is assumed that the longer persistence of OTC in plasma resulting with the latter two routes of administration was due to this irritation effect.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6649399     DOI: 10.1080/01652176.1983.9693891

Source DB:  PubMed          Journal:  Vet Q        ISSN: 0165-2176            Impact factor:   3.320


  4 in total

1.  Evaluation of Bioequivalence of Two Long-Acting 20% Oxytetracycline Formulations in Pigs.

Authors:  Zhixin Lei; Qianying Liu; Bing Yang; Saeed Ahmed; Jincheng Xiong; Tingting Song; Pin Chen; Jiyue Cao; Qigai He
Journal:  Front Vet Sci       Date:  2017-05-01

2.  Pharmacokinetic/pharmacodynamic integration and modelling of oxytetracycline for the porcine pneumonia pathogens Actinobacillus pleuropneumoniae and Pasteurella multocida.

Authors:  L Dorey; L Pelligand; Z Cheng; P Lees
Journal:  J Vet Pharmacol Ther       Date:  2017-01-16       Impact factor: 1.786

3.  Modelling Shows the Negative Impact of Age Dependent Pharmacokinetics on the Efficacy of Oxytetracycline in Young Steers.

Authors:  Peter Hekman; Johan Schefferlie; Ronette Gehring
Journal:  Front Vet Sci       Date:  2022-01-28

4.  Probing the in vitro cytotoxicity of the veterinary drug oxytetracycline.

Authors:  Zhenxing Chi; Rutao Liu; Hong You; Shanshan Ma; Hao Cui; Qiang Zhang
Journal:  PLoS One       Date:  2014-07-14       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.